2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.
Trial completed
Also in this update: Final enrollment: 18 participants (planned 20); Primary completion date changed from estimate of Dec 2, 2026 to Dec 18, 2025
Peking University Cancer Hospital & InstitutePhase 1 NCT06203119 Registry history of NCT06203119 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Sep 2026 to Mar 2027
Also in this update: Study completion pushed from Sep 2027 to Dec 2028
Peking University Cancer Hospital & InstitutePhase 2 NCT06141265 Registry history of NCT06141265 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-02 | NCT07854522 A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III… | Phase 4 | Not Yet Recruiting |
| 2026-09-29 | NCT07848243 Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Phase 2 | Recruiting |
| 2026-09-28 | NCT07843303 Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Phase 2 | Not Yet Recruiting |
| 2026-09-22 | NCT07833319 Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma… | Phase 2 | Recruiting |
| 2026-09-16 | NCT07822906 Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery | Not Yet Recruiting |
| Early Phase 1 | 4 | |
| Phase 1 | 7 | |
| Phase 1/2 | 5 | |
| Phase 2 | 42 | |
| Phase 2/3 | 2 | |
| Phase 3 | 3 | |
| Phase 4 | 3 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07854522 | A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III… | Melanoma | Not Yet Recruiting | 2026-10-02 |
| NCT07599137 | Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant Therapy | HR+/HER2- Breast Cancer | Not Yet Recruiting | 2026-05-20 |
| NCT07344974 | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity | Breast Cancer | Not Yet Recruiting | 2026-01-20 |
| Phase 3 | ||||
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer… | Rectal Cancer | Recruiting | 2024-01-29 |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in… | Acral Melanoma | Recruiting | 2023-09-06 |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients… | Renal Cell Carcinoma (RCC) | Not Yet Recruiting | 2025-09-10 |
| Phase 2/3 | ||||
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Not Yet Recruiting | 2026-06-17 |
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for… | Rectal Cancer | Not Yet Recruiting | 2024-06-05 |
| Phase 2 | ||||
| NCT06141265 | Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line… | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma | Recruiting | 2026-10-01 |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | Ovarian Carcinoma | Recruiting | 2026-10-01 |
| NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Lung Cancer (NSCLC) | Recruiting | 2026-09-29 |
| NCT06992362 | Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach | Hepatoid Adenocarcinoma of Stomach | Recruiting | 2026-09-22 |
| NCT07833319 | Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma… | Rectal Cancers | Recruiting | 2026-09-22 |
| NCT06768307 | Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus… | SCLC, Extensive Stage | Recruiting | 2026-08-17 |
| NCT07178340 | Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach | Hepatoid Adenocarcinoma of Stomach | Recruiting | 2025-12-02 |
| NCT06869213 | A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in… | Esophageal Cancer (EsC) | Recruiting | 2025-10-02 |
| NCT06869226 | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination… | Esophageal Cancer | Recruiting | 2025-10-02 |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus… | NK/T Cell Lymphoma | Recruiting | 2025-06-03 |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | Melanoma | Recruiting | 2025-03-03 |
| NCT06849167 | Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by… | Non-Small Cell Lung Cancer | Recruiting | 2025-02-27 |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced… | Collecting Duct Carcinoma | Recruiting | 2024-11-26 |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for… | Unresectable Hepatocellular Carcinoma | Recruiting | 2024-04-22 |
| NCT05985109 | KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer | Colorectal Cancer | Recruiting | 2023-10-26 |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to… | Digestive System Cancers | Recruiting | 2023-10-26 |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or… | Unresectable Hepatocellular Carcinoma | Recruiting | 2023-06-23 |
Lung Cancer (27) · Colorectal Cancer (22) · Breast Cancer (16) · Non-Small Cell Lung Cancer (NSCLC) (16) · Esophageal Cancer (10) · Small Cell Lung Cancer (9) · Gastric Cancer (6) · Melanoma (6) · HER2-Positive Cancer (4) · Kidney Cancer (4)